US Stock MarketDetailed Quotes
EDIT Editas Medicine
- 5.340
- -0.270-4.81%
Close Jul 24 16:00 ET
- 5.370
- +0.030+0.56%
Post 19:28 ET
439.15MMarket Cap-2579P/E (TTM)
5.740High5.325Low1.11MVolume5.570Open5.610Pre Close6.06MTurnover1.45%Turnover RatioLossP/E (Static)82.24MShares11.69052wk High1.49P/B407.99MFloat Cap4.45052wk Low--Dividend TTM76.40MShs Float99.950Historical High--Div YieldTTM7.40%Amplitude4.450Historical Low5.460Avg Price1Lot Size
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg
Editas Medicine Stock Forum
• Editing Genes | $CRISPR Therapeutics(CRSP.US)$ , $Intellia Therapeutics(NTLA.US)$ , $Beam Therapeutics(BEAM.US)$ , $Verve Therapeutics(VERV.US)$ , $Editas Medicine(EDIT.US)$
• Creating Therapies | $Prime Medicine(PRME.US)$ , $Sana Biotechnology(SANA.US)$
• Building DNA | $Twist Bioscience(TWST.US)$ , $Ginkgo Bioworks(DNA.US)$ , $Pacific Biosciences of California(PACB.US)$ , $Illumina(ILMN.US)$
• Dis...
NEWS
Editas Medicine Preclinical Data Highlights Advancement of in vivo Gene Editing Medicine Technologies at the American Society of Gene and Cell Therapy Annual Meeting
Editas Medicine demonstrated significant scientific advances in in vivo gene editing technologies, including lipid nanoparticle formulations for efficient delivery and guide RNA modifications to enhance editing potency.
The efficacy of AsCas12a nuclease in vivo was demonstrated by Editas Medicine, sho...
NEWS
Editas Medicine to Present Pre-clinical Data Demonstrating Progression of in vivo Medicines Pipeline at the American Society of Gene and Cell Therapy Annual Meeting
Gapping up
$Nike(NKE.US)$
(The sneaker behemoth added nearly 10% in premarket trading after a mixed earnings report. The company reported 94 cents per share and $12.94 billion in revenue, while analysts polled by LSEG forecast 75 cents and $12.98 million, respectively. Nike also reiterated mid-single digit full-year revenue growth guidance.)
$Uranium Energy(UEC.US)$
(The uranium miner added 2% after the company...
No comment yet